B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
Mayo Clinic
University of Arizona
City of Hope Medical Center
University of Giessen
Brown University
TG Therapeutics, Inc.
SecuraBio
Alliance for Clinical Trials in Oncology
University of California, Davis
Gilead Sciences
Wake Forest University Health Sciences
Aptevo Therapeutics
University of Washington
University of Arizona